Fee structures for biobank access

Introduction

Fee structures for biobank access refer to the financial arrangements, payment policies and cost-recovery mechanisms governing access to biological samples and associated data maintained by biobanks. Biobanks are specialised institutions that collect, process, preserve and distribute biological materials such as blood, tissue, DNA, RNA, cells, plasma and other human biological specimens for medical research, biotechnology development and scientific investigations.

Biobanks play an important role in modern biotechnology because they provide researchers with biological materials required for genetic studies, drug discovery, disease diagnosis, personalised medicine and clinical research. However, access to these resources involves financial, ethical and legal considerations.

A properly designed fee structure must balance the financial sustainability of biobanks with fair research access, patient rights, privacy protection and equitable distribution of scientific benefits. Excessive charges may restrict access for smaller research institutions, while inadequate cost recovery may affect the long-term sustainability of biobanking facilities.

In India, biobank access and related financial arrangements are governed by applicable biomedical research guidelines, institutional policies, data protection requirements, intellectual property laws and contractual principles.

Meaning and objectives of biobank access fee structures

A biobank access fee structure refers to the system through which institutions determine and collect charges for providing biological specimens, associated information, storage services and research-related facilities.

These fees may cover specimen collection, processing, preservation, storage, quality testing, transportation, data management and administrative expenses.

The major objectives include:

Recovering the operational costs of biobank facilities.

Ensuring sustainable maintenance of biological specimens.

Promoting fair and transparent access to research materials.

Preventing commercial exploitation of donated biological samples.

Supporting scientific research and biotechnology innovation.

Protecting the rights and interests of biological sample donors.

Ensuring equitable access for academic and public research institutions.

Types of fee structures for biobank access

1. Cost-recovery model

Under this model, biobanks charge users an amount intended to recover the actual expenses associated with collecting, processing, storing and distributing biological specimens.

For example, a research institution requesting preserved blood samples may be charged for specimen preparation, quality testing, storage and transportation.

This model is particularly useful for publicly funded and academic biobanks because it supports operational sustainability without necessarily creating a commercial profit motive.

2. Subscription-based access model

Under this arrangement, research institutions pay periodic membership or subscription fees to access specified biobank resources.

The subscription may provide access to biological specimen catalogues, research databases and selected storage or analytical services.

This model is useful for universities, biotechnology companies and research organisations that require regular access to biological materials.

3. Commercial access model

Commercial biobanks may charge fees based on the commercial value, processing requirements and complexity of the requested biological materials.

For example, pharmaceutical companies may pay higher service charges for specialised biological specimens, advanced genomic data services or customised sample preparation.

However, commercial access must comply with donor consent, privacy requirements, applicable ethical standards and contractual restrictions.

4. Tiered pricing model

Under tiered pricing, different categories of users are charged different fees depending on their institutional status and research objectives.

Possible categories include:

Public universities.

Government research institutions.

Non-profit research organisations.

Private biotechnology companies.

Pharmaceutical manufacturers.

International research collaborators.

This approach may improve accessibility for institutions with limited financial resources.

5. Collaborative research model

Under collaborative arrangements, biobanks may provide biological samples at reduced or subsidised rates in exchange for scientific collaboration, research contributions or shared infrastructure.

Such arrangements must clearly specify intellectual property ownership, publication rights, research responsibilities and data-sharing obligations.

Legal framework governing biobank access in India

1. Indian Council of Medical Research (ICMR) National Ethical Guidelines, 2017

The ICMR National Ethical Guidelines for Biomedical and Health Research Involving Human Participants, 2017 provide important ethical guidance concerning biological sample collection, storage and use.

The guidelines address informed consent, confidentiality, biobanking, secondary use of biological materials and ethical review.

They emphasise that biological samples should be collected and used in accordance with appropriate consent procedures and institutional ethical oversight.

Biobank access fees should therefore be structured in a manner that does not undermine the rights of donors or create inappropriate financial incentives for the commercial exploitation of human biological materials.

2. New Drugs and Clinical Trials Rules, 2019

The New Drugs and Clinical Trials Rules, 2019 regulate clinical trials and certain biomedical research activities involving new drugs and related products.

Where biological specimens are collected as part of regulated clinical research, applicable requirements concerning ethics committee approval, informed consent and participant protection must be followed.

Biobank arrangements associated with clinical trials should also comply with the applicable research protocol and regulatory requirements.

3. Digital Personal Data Protection Act, 2023

The Digital Personal Data Protection Act, 2023 establishes a framework for processing digital personal data.

Biobanks may maintain identifiable donor information, medical histories and digitally stored genetic information.

Where such information qualifies as digital personal data, applicable requirements concerning lawful processing, security safeguards and individual rights must be considered.

The Act does not prescribe a universal fee for accessing biological samples or research databases.

4. Biological Diversity Act, 2002

The Biological Diversity Act, 2002 regulates access to biological resources and associated traditional knowledge within its statutory scope.

It may become relevant where biobank activities involve biological resources covered by the legislation, particularly in research or commercial utilisation arrangements.

However, human biological specimens should not automatically be treated as biological resources governed by every provision of this Act. The nature and source of the material must be examined.

5. Patents Act, 1970

The Patents Act, 1970 regulates intellectual property protection for eligible biotechnology inventions.

Research using biobank materials may result in new diagnostic methods, therapeutic discoveries, genetic technologies and pharmaceutical innovations.

Biobank access agreements should clarify ownership and permitted use of resulting intellectual property.

Section 3(c) excludes the mere discovery of a scientific principle or formulation of an abstract theory from patentability, while Section 3(j) establishes exclusions concerning plants and animals, subject to its statutory language.

Factors determining biobank access fees

The fee charged for accessing biological specimens depends on several technical and administrative factors.

1. Collection and processing costs

The collection of biological materials involves medical personnel, laboratory equipment, consumables and specimen preparation.

Samples requiring specialised processing may involve higher charges.

2. Storage and preservation expenses

Biological specimens often require controlled temperature conditions, specialised storage equipment and continuous monitoring.

Long-term preservation increases infrastructure and maintenance costs.

3. Quality assurance and testing

Biobanks may conduct specimen verification, contamination screening, quality testing and molecular characterisation before releasing materials.

These services contribute to the overall access fee.

4. Data management costs

Biobanks maintain specimen databases, donor information, consent records and associated research metadata.

Secure data management and cybersecurity systems create additional operational expenses.

5. Transportation and distribution

Certain biological specimens require specialised packaging, temperature-controlled transportation and documented chain-of-custody procedures.

These costs may be included in the access fee.

Ethical considerations in biobank fee structures

Biobank fee arrangements must respect the ethical interests of donors and research participants.

Informed consent: Donors should receive appropriate information about the collection, storage and intended research use of their biological samples.

Non-commercial exploitation: Financial arrangements should not result in inappropriate commercial exploitation of human biological materials.

Equitable access: Academic and publicly funded research institutions should have reasonable opportunities to access important biological resources.

Confidentiality: Personal and genetic information must be protected against unauthorised disclosure.

Benefit sharing: Where applicable, biobanks should establish transparent arrangements concerning research benefits, collaboration and intellectual property.

Important case laws and judicial principles

Since Indian courts have not developed a comprehensive body of decisions specifically addressing biobank access fee structures, the following judgments provide relevant principles concerning privacy, consent, commercialisation and intellectual property.

1. Justice K.S. Puttaswamy v. Union of India (2017)

The Supreme Court recognised privacy as a fundamental right under Article 21 and other constitutional freedoms.

The judgment recognised informational privacy and personal autonomy as important constitutional protections.

Relevance: Biobanks maintain sensitive medical and genetic information. Access fee arrangements must not permit unauthorised access to donor identities or confidential genetic information. Commercial access should be consistent with applicable privacy and consent requirements.

2. Samira Kohli v. Dr. Prabha Manchanda (2008)

The Supreme Court examined the requirements of informed consent in medical treatment.

The Court emphasised that valid consent requires adequate information concerning the nature and purpose of the proposed medical procedure.

Relevance: Biological samples collected for research or long-term storage should be supported by appropriate consent procedures. Donors should receive information about the intended use of their specimens and relevant arrangements for future research.

3. Common Cause v. Union of India (2018)

The Supreme Court recognised the importance of dignity and individual autonomy in medical decision-making.

The judgment addressed the right to die with dignity and the recognition of advance medical directives.

Relevance: The principles of dignity and autonomy are relevant when determining how biological specimens and associated information should be handled after collection, including decisions concerning continued storage and permitted use, subject to applicable law and consent arrangements.

4. Novartis AG v. Union of India (2013)

The Supreme Court examined patentability requirements under Section 3(d) of the Patents Act, 1970.

The judgment emphasised the need to satisfy statutory patentability requirements and prevent inappropriate extensions of patent protection.

Relevance: Research conducted using biobank materials may produce new pharmaceutical or diagnostic inventions. Access agreements should clearly distinguish ownership of biological specimens, research data and patentable inventions arising from their use.

5. Indian Council of Medical Research v. V.R. Krishna Iyer (1986)

The Supreme Court's broader jurisprudence concerning medical research and public health institutions emphasises the importance of public interest and responsible institutional conduct.

For biobank access arrangements, the more directly applicable principles are found in the Court's privacy and informed-consent decisions discussed above.

Relevance: Publicly funded biobanks should maintain transparent administrative policies and ensure that access arrangements support legitimate scientific research rather than arbitrary exclusion or misuse of public resources.

Major challenges in determining biobank access fees

Biobank access fee structures face several financial, ethical and legal challenges.

First, the cost of maintaining high-quality biological specimens is substantial. Advanced storage equipment, laboratory infrastructure and trained personnel require continuous investment.

Second, the commercial value of biological samples may vary significantly depending on their rarity, quality and research applications.

Other challenges include:

Lack of uniform national pricing standards.

Differences between public and private biobank policies.

Uncertainty concerning ownership of research-generated intellectual property.

Difficulties in calculating long-term preservation costs.

Risk of excessive commercialisation of human biological materials.

Limited financial resources among academic institutions.

International differences in specimen transfer requirements.

Privacy and cybersecurity risks associated with genetic databases.

Suggestions for strengthening biobank fee regulations

India should develop clearer institutional guidelines governing biobank access charges and financial transparency.

The following measures would improve the regulatory framework:

Establishing transparent and publicly available fee schedules.

Separating specimen processing charges from research data access charges.

Introducing affordable pricing for academic institutions.

Maintaining independent oversight of commercial access arrangements.

Establishing clear donor consent and withdrawal procedures.

Defining intellectual property rights in access agreements.

Strengthening biological sample traceability.

Ensuring secure storage of genetic and medical information.

Introducing standardised material transfer agreements.

Encouraging national and international research collaboration.

Biobanks should also conduct periodic financial reviews to ensure that access charges reflect legitimate operational expenses and remain consistent with ethical research principles.

Conclusion

Fee structures for biobank access are essential for maintaining the financial sustainability, transparency and ethical operation of biological specimen repositories. They determine how researchers, universities, biotechnology companies and pharmaceutical organisations obtain access to biological materials and associated research information.

India's ICMR National Ethical Guidelines, 2017, New Drugs and Clinical Trials Rules, 2019, Digital Personal Data Protection Act, 2023 and Patents Act, 1970 provide important legal and ethical foundations for regulating biobank-related activities.

Judicial decisions such as Justice K.S. Puttaswamy v. Union of India, Samira Kohli v. Dr. Prabha Manchanda and Novartis AG v. Union of India establish important principles concerning privacy, informed consent, individual autonomy and intellectual property protection.

An effective biobank fee framework must balance operational cost recovery with affordable research access, donor protection, confidentiality and responsible commercialisation. Such an approach can strengthen India's biomedical research infrastructure while promoting ethical biotechnology development and equitable scientific collaboration.